438O Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC
Titel:
438O Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC
Auteur:
Park, K. Barlesi, F. Ciardiello, F. von Pawel, J. Gadgeel, S. Hida, T. Kowalski, D. Dols, M. Cobo Cortinovis, D. Leach, J. Polikoff, J. Gandara, D.R. Barrios, C. Chen, D.S. He, P. Kowanetz, M. Ballinger, M. Waterkamp, D. Sandler, A. Rittmeyer, A.